var data={"title":"Candidemia and invasive candidiasis in children: Management","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Candidemia and invasive candidiasis in children: Management</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/contributors\" class=\"contributor contributor_credentials\">Judith R Campbell, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/contributors\" class=\"contributor contributor_credentials\">Debra L Palazzi, MD, MEd</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 09, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The term candidemia describes the presence of <em>Candida</em> species in the blood. <em>Candida</em> in a blood culture should prompt a search for the source; it should never be viewed as a contaminant. Invasive candidiasis encompasses both candidemia and deep-seated (ie, visceral) candidiasis (which may occur with or without candidemia) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/1\" class=\"abstract_t\">1</a>].</p><p>The management of candidemia and invasive candidiasis in children will be discussed here. An overview of candidal infections and the clinical manifestations and diagnosis of candidemia and invasive candidiasis in children, candidal infections in neonates, and candidal infections in adults are discussed separately:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=candida-infections-in-children\" class=\"medical medical_review\">&quot;Candida infections in children&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-and-risk-factors-for-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Epidemiology and risk factors for Candida infection in neonates&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of Candida infection in neonates&quot;</a> and <a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Treatment of Candida infection in neonates&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">&quot;Epidemiology and pathogenesis of candidemia in adults&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults&quot;</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H3500291199\"><span class=\"h1\">HIGH SUSPICION FOR INVASIVE CANDIDIASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifungal therapy may be indicated pending laboratory identification of <em>Candida</em> for patients in whom there is a high suspicion for invasive candidiasis. We initiate antifungal therapy in children with significant risk factors for invasive candidiasis (eg, ongoing fever despite broad-spectrum antibiotics in immunocompromised patients) or characteristic examination findings (eg, retinal (<a href=\"image.htm?imageKey=ID%2F58685%7EID%2F73318\" class=\"graphic graphic_picture graphicRef58685 graphicRef73318 \">picture 1A-B</a>) or skin lesions (<a href=\"image.htm?imageKey=ID%2F55977%7EID%2F75717\" class=\"graphic graphic_picture graphicRef55977 graphicRef75717 \">picture 2A-B</a>)).</p><p class=\"headingAnchor\" id=\"H2519417445\"><span class=\"h1\">DOCUMENTED INVASIVE CANDIDIASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of candidemia and invasive candidiasis requires treatment with an antifungal agent and adequate source control.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Choice of antifungal therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifungal therapy should be initiated as soon as possible after <em>Candida</em> is identified in a blood culture or other appropriate laboratory specimens (eg, urine culture, biopsy specimen culture). Early initiation of antifungal therapy (ie, within 24 hours of obtaining blood cultures) is associated with enhanced survival in adult patients with invasive candidiasis [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/2-4\" class=\"abstract_t\">2-4</a>].</p><p>The choice of antifungal agent is guided by clinical features (age, hemodynamic <span class=\"nowrap\">stability/severity</span> of illness, site of infection, baseline renal function, neutropenia) and the infecting <em>Candida</em> species (which affects susceptibility patterns) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/5,6\" class=\"abstract_t\">5,6</a>]. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1690258277\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'Susceptibility patterns'</a>.)</p><p>Our approach to antifungal therapy in children with invasive candidiasis is generally in keeping with the 2016 Infectious Diseases Society of America (IDSA) and 2012 European Society for Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of candidiasis (<a href=\"image.htm?imageKey=PEDS%2F109381\" class=\"graphic graphic_table graphicRef109381 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/7,8\" class=\"abstract_t\">7,8</a>]. The treatment of candidiasis in neonates is discussed separately. (See <a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">&quot;Treatment of Candida infection in neonates&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2519344657\"><span class=\"h3\">Pending speciation and susceptibility testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pending speciation and results of susceptibility testing, the choice of therapy for <em>Candida</em> is influenced by whether the patient is known to be colonized with resistant <em>Candida</em> species, if the patient has developed candidemia despite antifungal prophylaxis, and the proportion of candidemia isolates due to resistant species within a particular medical center. In addition, a positive germ tube test (if performed) suggests <em>C. albicans</em>, which is generally susceptible to <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a>. When the <em>Candida</em> species and susceptibility are known, antifungal therapy can be adjusted as indicated. (See <a href=\"#H275376940\" class=\"local\">'Targeted therapy'</a> below.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nonneutropenic patients</strong> &ndash; Pending speciation and susceptibility testing, for nonneutropenic children with invasive candidiasis that does not involve the eye, central nervous system (CNS), or urinary tract, we suggest treatment with an echinocandin (eg, <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">micafungin</a>, <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">caspofungin</a>) or a lipid formulation of amphotericin B. <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluconazole</a> is an acceptable alternative in patients who are not critically ill and those unlikely to have a fluconazole-resistant infection (eg, positive germ tube test [if performed], lack of prior fluconazole exposure). Echinocandins are not recommended for candidiasis involving the eye, CNS, or urinary tract because they have relatively poor penetration at these sites. </p><p/><p class=\"bulletIndent1\">Although experience with <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">caspofungin</a>, <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">micafungin</a>, and <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> in children is limited [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/9-13\" class=\"abstract_t\">9-13</a>], these agents have been shown to be efficacious in nonneutropenic adults [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/14,15\" class=\"abstract_t\">14,15</a>]. (See <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H218866864\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'Nonneutropenic patients'</a>.)</p><p/><p class=\"bulletIndent1\">Several large randomized trials in adults have shown that <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> is as effective as <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a> for the treatment of candidemia [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/16-19\" class=\"abstract_t\">16-19</a>]. Similar comparative trials in children have not been reported, but case reports and noncomparative trials of fluconazole in children suggest that it is safe, well-tolerated, and effective [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/20-22\" class=\"abstract_t\">20-22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Neutropenic patients</strong> &ndash; Pending speciation and susceptibility testing, for neutropenic children with invasive candidiasis that does not involve the eye, CNS, or urinary tract, we suggest treatment with an echinocandin (eg, <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">micafungin</a>, <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">caspofungin</a>) or a lipid formulation of amphotericin B, although use of the latter may be limited by toxicity in this patient population. <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluconazole</a> is an acceptable alternative in patients who are not critically ill and those without prior azole exposure. Echinocandins are not recommended for candidiasis involving the eye, CNS, or urinary tract because they have relatively poor penetration at these sites.</p><p/><p class=\"bulletIndent1\">Less information is available to guide antifungal therapy in neutropenic than nonneutropenic patients with candidemia. Limited data from studies in adults support the use of amphotericin B, an echinocandin, or <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> in neutropenic adults, but there are few studies in children. We avoid fluconazole in children who are clinically unstable, have disseminated infection, and have received fluconazole for prophylaxis. (See <a href=\"#H327877656\" class=\"local\">'Antifungal agents'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H275376940\"><span class=\"h3\">Targeted therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antifungal therapy can be adjusted as indicated when the susceptibility pattern is available <span class=\"nowrap\">and/or</span> the species is identified. However, in hospitals where susceptibility testing is performed at an outside reference laboratory, prompt adjustment of antifungal therapy (eg, from an echinocandin to <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a>) may not be feasible. </p><p><em>C. albicans</em> is the most common cause of candidemia, but nonalbicans species are increasingly isolated. Among nonalbicans species, <em>C. glabrata</em> and <em>C. parapsilosis</em> are most prominent, followed by <em>C. tropicalis</em> and <em>C. krusei.</em> Antifungal susceptibility patterns and minimal inhibitory concentrations may vary according to species. (See <a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-clinical-manifestations-and-diagnosis#H2\" class=\"medical medical_review\">&quot;Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis&quot;, section on 'Epidemiology'</a> and <a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults#H1690258277\" class=\"medical medical_review\">&quot;Treatment of candidemia and invasive candidiasis in adults&quot;, section on 'Susceptibility patterns'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>C. albicans</em></strong><strong>, </strong><strong><em>C. parapsilosis</em></strong><strong>, and </strong><strong><em>C. tropicalis</em></strong> &ndash; <em>C. albicans</em>, <em>C. parapsilosis</em>, and <em>C. tropicalis</em> generally are susceptible to amphotericin B, azoles, and echinocandins, and initial therapy with any of them is reasonable for patients with invasive candidiasis that does not involve the eye, CNS, or urinary tract. Echinocandins are not recommended for candidiasis involving the eye, CNS, or urinary tract because they have relatively poor penetration at these sites. <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Voriconazole</a> is also not recommended for patients with urinary candidiasis because the active form is minimally excreted in the urine.</p><p/><p class=\"bulletIndent1\">Although there is concern that <em>C. parapsilosis</em> may be less susceptible to echinocandins because of innately higher minimum inhibitory concentrations, clinical data are lacking. </p><p/><p class=\"bulletIndent1\">For patients with <em>C. albicans</em>, <em>C. parapsilosis</em>, or <em>C. tropicalis</em>, we suggest transitioning from initial antifungal therapy to <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> in patients who are clinically stable, have fluconazole-susceptible isolates, and negative repeat blood cultures.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>C. glabrata</em></strong> &ndash; For children with invasive candidiasis due to C. glabrata, we usually treat with amphotericin B. <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Voriconazole</a> may be an alternative for susceptible isolates but is not recommended for infection involving the urinary tract. <strong>Many </strong><strong><em>C. glabrata</em></strong><strong> species are resistant to </strong><a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a>. Although echinocandins are preferred for adult patients, some studies have shown increased rates of echinocandin resistance [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/23-26\" class=\"abstract_t\">23-26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>C. krusei</em></strong> &ndash; For children with invasive candidiasis due to <em>C. krusei</em>, we usually treat with amphotericin B, an echinocandin, or <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a>, if the isolate is susceptible.</p><p/><p class=\"bulletIndent1\">For patients with urinary candidiasis, <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> is not recommended because the active form is minimally excreted in the urine. Echinocandins are not recommended for candidiasis involving the eye, CNS, or urinary tract because they have relatively poor penetration at these sites.</p><p/><p class=\"bulletIndent1\"><em>C. krusei</em> has decreased susceptibility to amphotericin B, requiring higher doses. <em>C. krusei</em> is intrinsically resistant to <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a>. Resistance to <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> varies geographically.</p><p/><p class=\"headingAnchor\" id=\"H237362476\"><span class=\"h2\">Monitoring response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We obtain daily or every other day blood cultures after initiating treatment for candidemia to confirm the date of sterilization (which determines the duration of treatment). (See <a href=\"#H1550496714\" class=\"local\">'Duration of antifungal therapy'</a> below.)</p><p>Children with invasive candidiasis without candidemia generally are monitored for resolution of signs and symptoms of infection as appropriate (eg, resolution of fever and characteristic lesions on abdominal imaging).</p><p class=\"headingAnchor\" id=\"H2508085457\"><span class=\"h3\">Persistent candidemia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>If blood cultures remain positive for more than three days in a patient receiving appropriate antifungal therapy with adequate source control, then a search for a metastatic focus or endocarditis needs to be undertaken:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients should be examined for thrombophlebitis or other focal evidence of infection (eg, focal muscle pain, abdominal pain). Signs and symptoms of infection guide the next steps in the evaluation, which often includes advanced imaging techniques (eg, ultrasonography, computed tomography, magnetic resonance imaging), especially in immunocompromised hosts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An echocardiogram generally is recommended because murmur may be absent in children with endocarditis. (See <a href=\"topic.htm?path=infective-endocarditis-in-children#H7\" class=\"medical medical_review\">&quot;Infective endocarditis in children&quot;, section on 'Clinical manifestations'</a>.)</p><p/><p>In neutropenic patients with persistent fungemia despite appropriate antifungal therapy, central catheters should be removed. Removal of central catheters generally is recommended as soon as feasible in the initial management of candidemia in nonneutropenic patients. However, if catheters initially are retained, their removal is necessary once persistent candidemia develops. (See <a href=\"#H2934778652\" class=\"local\">'Source control'</a> below.)</p><p class=\"headingAnchor\" id=\"H1550496714\"><span class=\"h2\">Duration of antifungal therapy</span></p><p class=\"headingAnchor\" id=\"H2235653712\"><span class=\"h3\">Suggested duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The appropriate duration of therapy for invasive candidiasis has not been studied. Our suggested durations are provided below (<a href=\"image.htm?imageKey=PEDS%2F109381\" class=\"graphic graphic_table graphicRef109381 \">table 1</a>): </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with candidemia and no evidence of metastatic foci of infection, we generally treat for a minimum of two weeks after blood cultures become negative. This is the duration that has been used in most clinical trials in adults [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/16\" class=\"abstract_t\">16</a>] and is the recommended duration in the 2016 IDSA and 2012 ESCMID practice guidelines [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/7,8\" class=\"abstract_t\">7,8</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with central venous catheter-associated candidemia, we generally treat for two weeks after catheter removal and candidemia has cleared. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with central venous catheter-associated candidemia in which catheter retention is attempted, longer durations of therapy generally are needed. </p><p/><p class=\"bulletIndent1\">In such cases, performing an ultrasound of large veins to evaluate for thrombophlebitis may be prudent. Patients with <em>Candida</em> suppurative thrombophlebitis require catheter removal and incision and drainage or resection of the vein, if feasible. Antifungal treatment of <em>Candida</em> suppurative thrombophlebitis is generally for at least two weeks after candidemia has cleared and preferably when the thrombus has resolved. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with deep-seated invasive candidiasis (eg, endocarditis or other metastatic focus of infection), longer durations of therapy are necessary and should be determined in consultation with an infectious diseases clinician. </p><p/><p class=\"bulletIndent1\">We typically treat endocarditis for a minimum of six weeks in patients with native value disease, but longer durations may be required in those with complications such as perivalvular abscesses. For patients with prosthetic valve endocarditis caused by <em>Candida</em> species, chronic suppressive antifungal therapy usually is recommended to prevent recurrence. </p><p/><p class=\"headingAnchor\" id=\"H1715923409\"><span class=\"h3\">Switching to oral therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Data regarding when to switch to oral azole therapy in children are lacking. Switching to oral azole therapy may be reasonable in select patients without disseminated infection who are clinically stable, have azole-susceptible isolates, negative repeat blood cultures, and can tolerate oral medication.</p><p class=\"headingAnchor\" id=\"H2934778652\"><span class=\"h2\">Source control</span></p><p class=\"headingAnchor\" id=\"H3634349987\"><span class=\"h3\">Central venous catheter</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In addition to prompt initiation of antifungal therapy, we recommend that central venous catheters be removed in nonneutropenic children with candidemia if the catheter is thought to be the source and it can be removed safely. Central venous catheters often are the source of candidemia in patients without neutropenia [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/27,28\" class=\"abstract_t\">27,28</a>]. In patients with neutropenia, the gastrointestinal tract is a frequent source of invasive candidiasis, so the decision regarding catheter removal should be considered on an individual basis.</p><p>When appropriate, the catheter should be removed as soon as possible [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/8,29\" class=\"abstract_t\">8,29</a>]. Fungemia clears more quickly when catheters are removed [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/30,31\" class=\"abstract_t\">30,31</a>], and in observational studies, retention of the central venous catheter has been associated with increased mortality in children [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/28,32,33\" class=\"abstract_t\">28,32,33</a>]. Although successful treatment without catheter removal has been described using antifungal lock therapy in addition to systemic antifungal therapy [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/34-39\" class=\"abstract_t\">34-39</a>], additional studies are necessary before this approach can be routinely recommended.</p><p class=\"headingAnchor\" id=\"H3275888630\"><span class=\"h3\">Other foci of infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sources of infection other than a central venous catheter are more common in neutropenic than nonneutropenic patients. Other foci of invasive candidiasis include abscesses or other fluid collections in the abdomen, chest, or bones. In addition to antifungal therapy, successful management of invasive candidiasis requires surgical or radiologic procedures to remove or drain these fluid collections [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/4\" class=\"abstract_t\">4</a>].</p><p class=\"headingAnchor\" id=\"H1984269720\"><span class=\"h2\">Outcome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Untreated candidemia has a mortality rate of over 60 percent [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/40\" class=\"abstract_t\">40</a>]. With treatment, the overall mortality of candidemia in children is approximately 9 to 40 percent [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/41-43\" class=\"abstract_t\">41-43</a>].</p><p>Factors associated with increased mortality include [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/2-4,41,44,45\" class=\"abstract_t\">2-4,41,44,45</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Delayed initiation or inadequate dosing of antifungal therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Septic shock</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inadequate source control (ie, failure to remove a central venous catheter or to drain or surgically remove a deep-seated source)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased severity of illness (eg, as determined by a validated scoring system)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infection with an antifungal-resistant strain</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunosuppressive therapy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The infecting <em>Candida</em> species (<em>C. albicans</em> and <em>C. glabrata</em> have increased mortality compared with <em>C. parapsilosis</em>)</p><p/><p class=\"headingAnchor\" id=\"H1402641259\"><span class=\"h1\">EMPIRIC ANTIFUNGAL THERAPY FOR AT-RISK PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antifungal therapy describes provision of antifungal therapy to patients at risk for invasive candidiasis who do not have documented invasive candidiasis, but who may nonetheless have invasive candidiasis, given the presumably low sensitivity of microbiologic tests for <em>Candida</em>. (See <a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-clinical-manifestations-and-diagnosis#H3028289430\" class=\"medical medical_review\">&quot;Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis&quot;, section on 'Microbiologic studies'</a>.)</p><p class=\"headingAnchor\" id=\"H2317282572\"><span class=\"h2\">Nonneutropenic patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest empiric antifungal therapy for nonneutropenic children who are hospitalized in the intensive care unit with risk factors for invasive candidiasis and no other known cause of fever or sepsis. Risk factors for invasive candidiasis in children include immune suppression, damage to the gastrointestinal mucosa, central venous catheter, broad-spectrum antibiotics, parenteral nutrition, renal failure requiring hemodialysis, and mechanical ventilation. (See <a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-clinical-manifestations-and-diagnosis#H3\" class=\"medical medical_review\">&quot;Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis&quot;, section on 'Risk factors'</a>.)</p><p>The initiation of empiric antifungal therapy should be based on the clinical assessment of the patient in addition to surrogate markers of invasive candidiasis and data regarding the patient's colonization status (ie, <em>Candida</em> isolated in cultures from nonsterile sites), if available. A general approach is to initiate empiric antifungal therapy in critically ill patients with ongoing fever despite antibiotic therapy who have <em>Candida</em> colonization and risk factors for candidemia.</p><p>In a 2016 meta-analysis of 17 studies (2024 participants), empiric antifungal treatment reduced the risk of proven invasive fungal infection (35.2 versus 64.8 percent; risk ratio 0.57, 95% CI 0.39-0.83; 17 studies, 2024 participants); however, it had no effect on mortality (approximately 24 percent) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/46\" class=\"abstract_t\">46</a>].</p><p>The duration of empiric antifungal therapy in patients without evidence supporting a fungal infection depends upon the clinical response to empiric therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No clinical response &ndash; Empiric antifungal therapy should be stopped after four to five days in patients who have no clinical response and lack supporting evidence for fungal infection (ie, negative cultures, negative blood-based markers of invasive candidiasis).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical response &ndash; In patients who have a clinical response to therapy but have negative cultures <span class=\"nowrap\">and/or</span> surrogate markers of invasive candidiasis, data are lacking about the appropriate duration of antifungal therapy. However, most experts would recommend a treatment course for presumptive candidemia. We agree with this approach.</p><p/><p class=\"headingAnchor\" id=\"H1829865803\"><span class=\"h2\">Neutropenic patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Empiric antifungal therapy may be given routinely to children with neutropenia and fever that have failed to respond to four to five days of antibiotics because they are at substantial increased risk for invasive candidiasis. This is discussed separately. (See <a href=\"topic.htm?path=fever-in-children-with-chemotherapy-induced-neutropenia#H23804813\" class=\"medical medical_review\">&quot;Fever in children with chemotherapy-induced neutropenia&quot;, section on 'Antifungal therapy'</a> and <a href=\"topic.htm?path=evaluation-and-management-of-fever-in-children-with-non-chemotherapy-induced-neutropenia#H14\" class=\"medical medical_review\">&quot;Evaluation and management of fever in children with non-chemotherapy-induced neutropenia&quot;, section on 'Antifungal therapy'</a>.)</p><p class=\"headingAnchor\" id=\"H327877656\"><span class=\"h1\">ANTIFUNGAL AGENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Amphotericin B and <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> have been used in the treatment of candidemia in children because of their long-standing safety and efficacy. However, lipid formulations of amphotericin B, other azoles, and echinocandins are increasingly used in children as information about their safety, efficacy, and pharmacokinetics becomes available [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/47-49\" class=\"abstract_t\">47-49</a>].</p><p class=\"headingAnchor\" id=\"H2040771150\"><span class=\"h2\">Amphotericin B deoxycholate</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most of the experience with treating fungal infections in children has been with <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a> (conventional amphotericin). However, use of amphotericin B deoxycholate beyond the neonatal period has fallen out of favor because of drug-associated toxicities. &#160;</p><p>Although very young children tend to tolerate <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a> better than adults and have less nephrotoxicity, we suggest lipid amphotericin B for most children including those with underlying renal insufficiency. Glomerular filtration rate (GFR) can be estimated with the following formula: GFR in <span class=\"nowrap\">mL/min</span> per 1.73 m<sup>2</sup> = (0.41 x height in cm) <span class=\"nowrap\">/</span> serum creatinine in <span class=\"nowrap\">mg/dL</span> [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/50\" class=\"abstract_t\">50</a>]. The threshold for choosing lipid amphotericin B is individualized according to the need for other nephrotoxic drugs and trends in GFR over time.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The recommended dose of <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a> for infants and children is 1.0 <span class=\"nowrap\">mg/kg</span> per day.</p><p/><p class=\"bulletIndent1\">Doses as high as 1.5 <span class=\"nowrap\">mg/kg</span> per day have been used for meningitis or disseminated infection with focal liver or renal disease, but if higher doses are needed, changing to a lipid formulation may be warranted. (See <a href=\"#H2445034808\" class=\"local\">'Lipid amphotericin B'</a> below.)</p><p/><p>During therapy with <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a>, we suggest close monitoring of serum creatinine and electrolytes, including magnesium and potassium. Serum potassium should be &ge;3 <span class=\"nowrap\">mmol/L</span> (3 <span class=\"nowrap\">mEq/L)</span> before administration of amphotericin B. Daily laboratory monitoring may be required. Lipid formulations of amphotericin or an echinocandin should be used if there is a rise in serum creatinine [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">&quot;Amphotericin B nephrotoxicity&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2445034808\"><span class=\"h2\">Lipid amphotericin B</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lipid amphotericin B preparations (eg, <a href=\"topic.htm?path=liposomal-amphotericin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">liposomal amphotericin B</a>, <a href=\"topic.htm?path=amphotericin-b-lipid-complex-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B lipid complex</a> [ABLC], <a href=\"topic.htm?path=amphotericin-b-cholesteryl-sulfate-complex-united-states-not-available-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B cholesteryl sulfate complex</a> [ABCD, not available in the United States]) are preferred for most children including those who are receiving other nephrotoxic agents (eg, posttransplantation).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The usual dose is 3 to 5 <span class=\"nowrap\">mg/kg</span> IV once per day; 5 <span class=\"nowrap\">mg/kg</span> per day may be warranted if <em>C. glabrata</em> or <em>C. krusei</em> is suspected or identified.</p><p/><p>Although the incidence of decreased renal function and infusion-related adverse events with lipid formulations of amphotericin B are lower than rates observed with <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-pediatric-drug-information\" class=\"drug drug_pediatric\">amphotericin B deoxycholate</a>, these complications do occur. Therefore, during therapy with lipid formulations of amphotericin B, we suggest close monitoring of serum creatinine and electrolytes, including magnesium and potassium. Serum potassium should be &ge;3 <span class=\"nowrap\">mmol/L</span> (3 <span class=\"nowrap\">mEq/L)</span> before administration of lipid formulations of amphotericin B. Daily laboratory monitoring may be required. An alternative antifungal agent (eg, echinocandin, azole) may be needed if there is a rise in serum creatinine or persistent derangement of serum electrolytes.</p><p>The pharmacokinetics of lipid formulations in children are similar to those in adults [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/51\" class=\"abstract_t\">51</a>]. (See <a href=\"topic.htm?path=pharmacology-of-amphotericin-b#H16\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;, section on 'Lipid-based amphotericin B formulations'</a>.)</p><p class=\"headingAnchor\" id=\"H1313370116\"><span class=\"h2\">Azole antifungal agents</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Azole antifungal agents available for the treatment of candidemia and invasive candidiasis in children include <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> and <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a>. The safety and efficacy of other azole antifungal agents (eg, <a href=\"topic.htm?path=posaconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">posaconazole</a>, <a href=\"topic.htm?path=isavuconazole-isavuconazonium-sulfate-drug-information\" class=\"drug drug_general\">isavuconazole</a>) in the treatment of invasive candidiasis in children have not been adequately studied.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluconazole</a> &ndash; Fluconazole is used more often than <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> in the treatment of invasive candidiasis in children. Risk factors for fluconazole resistance include neutropenia and recent azole use. Fluconazole should not be used if <em>C. krusei</em> is suspected or identified. <em>C. krusei</em> is intrinsically resistant to fluconazole [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/52\" class=\"abstract_t\">52</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The recommended dose of <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> for children is 12 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/53\" class=\"abstract_t\">53</a>].</p><p/><p class=\"bulletIndent1\">Children require higher doses of <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> than adults because the half-life is shorter in children [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/53,54\" class=\"abstract_t\">53,54</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Voriconazole</a> &ndash; Voriconazole generally is used as step-down therapy in patients with invasive infection due to <em>C. krusei</em> and <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a>-resistant, voriconazole-susceptible <em>C. glabrata</em>.</p><p/><p class=\"bulletIndent1\"><a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">Voriconazole</a> is not recommended for patients with urinary candidiasis because the active form is minimally excreted in the urine.</p><p/><p class=\"bulletIndent1\">The recommended dose of <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> for children varies according to age [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/55,56\" class=\"abstract_t\">55,56</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>&lt;12 years &ndash; 9 <span class=\"nowrap\">mg/kg</span> twice daily as a loading dose for the first day and then 8 <span class=\"nowrap\">mg/kg</span> every 12 hours</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>&ge;12 years &ndash; 6 <span class=\"nowrap\">mg/kg</span> twice daily as a loading dose for the first day and then 4 <span class=\"nowrap\">mg/kg</span> every 12 hours</p><p/><p class=\"bulletIndent1\">Younger children require higher doses of <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> than older children and adults because of differing elimination patterns (linear elimination until approximately 12 years of age and nonlinear elimination thereafter) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/55\" class=\"abstract_t\">55</a>].</p><p/><p class=\"bulletIndent1\">We suggest that serum <a href=\"topic.htm?path=voriconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">voriconazole</a> concentrations be monitored and dose adjusted to maintain trough concentration between 1 and 5 <span class=\"nowrap\">mcg/mL</span> [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/57-59\" class=\"abstract_t\">57-59</a>]. Trough concentrations &gt;5 <span class=\"nowrap\">mcg/mL</span> are associated with toxicity [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/58,59\" class=\"abstract_t\">58,59</a>]. In observational studies, the pharmacokinetics of voriconazole have varied markedly from patient to patient [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/60-62\" class=\"abstract_t\">60-62</a>]. In one study, voriconazole trough concentrations of &gt;1 <span class=\"nowrap\">mcg/mL</span> were associated with increased survival from invasive fungal infection (9 of 46 children had invasive candidiasis) [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/60\" class=\"abstract_t\">60</a>]. Pending prospective studies confirming these results, it is prudent to maintain a trough concentration of at least 1 <span class=\"nowrap\">mcg/mL</span>.</p><p/><p class=\"headingAnchor\" id=\"H2984100972\"><span class=\"h2\">Echinocandins</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Echinocandins include <a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">caspofungin</a>, <a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">anidulafungin</a>, and <a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">micafungin</a>. Echinocandins are first-line agents for the treatment of invasive candidiasis in adults, based upon randomized trials demonstrating that they are as safe and effective as amphotericin B or <a href=\"topic.htm?path=fluconazole-pediatric-drug-information\" class=\"drug drug_pediatric\">fluconazole</a> [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/14,63-65\" class=\"abstract_t\">14,63-65</a>]. Although there are fewer data than in adults [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/66-73\" class=\"abstract_t\">66-73</a>], echinocandins appear to be safe in children and are frequently used for suspected or confirmed invasive candidiasis.</p><p>Echinocandins are not recommended for candidiasis involving the eye, central nervous system (CNS), or urinary tract because they have relatively poor penetration at these sites.</p><p>General dosing guidelines for echinocandins in children are as provided below [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/68,74-79\" class=\"abstract_t\">68,74-79</a>]. Dosing regimens have not been standardized in children. We suggest that echinocandin regimens be discussed with an infectious diseases pharmacist or clinician before starting therapy.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=caspofungin-pediatric-drug-information\" class=\"drug drug_pediatric\">Caspofungin</a> &ndash; Caspofungin is available for the treatment of candidemia and invasive candidiasis and for empirical therapy for suspected fungal infection in children with fever and neutropenia age &ge;3 months. Caspofungin is dosed by body surface area rather than weight [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/67-70\" class=\"abstract_t\">67-70</a>]:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The recommended regimen is a single loading dose of 70 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day (maximum dose 70 mg), followed by 50 <span class=\"nowrap\">mg/m<sup>2</sup></span> per day (maximum dose 70 mg)</p><p/><p class=\"bulletIndent1\">Patients receiving other medications that induce drug clearance (eg, <a href=\"topic.htm?path=phenytoin-pediatric-drug-information\" class=\"drug drug_pediatric\">phenytoin</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>), may require increased doses (within the maximum dose of 70 mg).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=micafungin-pediatric-drug-information\" class=\"drug drug_pediatric\">Micafungin</a> &ndash; Micafungin is available for the treatment of candidemia, invasive candidiasis, <em>Candida</em> peritonitis and abscesses, esophageal candidiasis, and prophylaxis of <em>Candida</em> infections in patients undergoing hematopoietic cell transplantation &ge;4 months of age [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/80\" class=\"abstract_t\">80</a>]. The suggested dose varies according to the indication and clinical response.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For the treatment of candidemia and invasive candidiasis the initial dose is 2 to 3 <span class=\"nowrap\">mg/kg</span> per day (maximum 150 mg per day). Increased doses (up to 4 <span class=\"nowrap\">mg/kg</span> per day) may be necessary in children &lt;40 kg or those without an adequate clinical response to a lower dose [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=anidulafungin-drug-information\" class=\"drug drug_general\">Anidulafungin</a> &ndash; Anidulafungin is not approved by the US Food and Drug Administration (FDA) for use in children. In cases in which there is no alternative, the dose should be 1.5 <span class=\"nowrap\">mg/kg</span> per day [<a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/68\" class=\"abstract_t\">68</a>].</p><p/><p class=\"headingAnchor\" id=\"H4053869140\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Candidiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H275376660\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The term candidemia describes the presence of <em>Candida</em> species in the blood. <em>Candida</em> in a blood culture should prompt a search for the source; it should never be viewed as a contaminant. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antifungal therapy should be initiated as soon as possible after <em>Candida</em> is identified in a blood culture. The choice of antifungal agent is guided by clinical features (age, hemodynamic <span class=\"nowrap\">stability/severity</span> of illness, site of infection, baseline renal function, neutropenia) and the infecting <em>Candida</em> species (<a href=\"image.htm?imageKey=PEDS%2F109381\" class=\"graphic graphic_table graphicRef109381 \">table 1</a>). (See <a href=\"#H11\" class=\"local\">'Choice of antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We obtain daily or every other day blood cultures after initiating treatment for invasive candidiasis to confirm the date of sterilization, which affects the duration of treatment. (See <a href=\"#H237362476\" class=\"local\">'Monitoring response'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For children with candidemia and no evidence of metastatic foci of infection, we generally treat for a minimum of two weeks after blood cultures become negative (<a href=\"image.htm?imageKey=PEDS%2F109381\" class=\"graphic graphic_table graphicRef109381 \">table 1</a>). For children with deep-seated invasive candidiasis (eg, endocarditis or other metastatic focus of infection), longer durations of therapy are necessary and should be determined in consultation with an infectious diseases clinician. (See <a href=\"#H1550496714\" class=\"local\">'Duration of antifungal therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In addition to prompt initiation of antifungal therapy, we recommend that central venous catheters be removed in nonneutropenic children with candidemia if the catheter is thought to be the source and it can be removed safely. In patients with neutropenia, the gastrointestinal tract is a frequent source of invasive candidiasis, so the decision regarding catheter removal should be considered on an individual basis. (See <a href=\"#H2934778652\" class=\"local\">'Source control'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Even with appropriate therapy, the mortality of candidemia is approximately 9 to 40 percent. Factors associated with increased mortality include delayed initiation or inadequate dosing of antifungal therapy, inadequate source control, increased severity of illness, immunosuppressive therapy. (See <a href=\"#H1984269720\" class=\"local\">'Outcome'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1726014949\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Carol A Kauffman, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/1\" class=\"nounderline abstract_t\">Clancy CJ, Nguyen MH. Finding the &quot;missing 50%&quot; of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 2013; 56:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/2\" class=\"nounderline abstract_t\">Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 2006; 43:25.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/3\" class=\"nounderline abstract_t\">Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/4\" class=\"nounderline abstract_t\">Kollef M, Micek S, Hampton N, et al. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis 2012; 54:1739.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/5\" class=\"nounderline abstract_t\">Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007; 119:772.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/6\" class=\"nounderline abstract_t\">Steinbach WJ. Antifungal agents in children. Pediatr Clin North Am 2005; 52:895.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/7\" class=\"nounderline abstract_t\">Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18 Suppl 7:38.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/8\" class=\"nounderline abstract_t\">Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/9\" class=\"nounderline abstract_t\">Franklin JA, McCormick J, Flynn PM. Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr Infect Dis J 2003; 22:747.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/10\" class=\"nounderline abstract_t\">Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006; 25:1186.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/11\" class=\"nounderline abstract_t\">Koo A, Sung L, Allen U, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J 2007; 26:854.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/12\" class=\"nounderline abstract_t\">Pasqualotto AC, Shah M, Wynn R, Denning DW. Voriconazole plasma monitoring. Arch Dis Child 2008; 93:578.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/13\" class=\"nounderline abstract_t\">Viscoli C, Bassetti M, Castagnola E, et al. Micafungin for the treatment of proven and suspected invasive candidiasis in children and adults: findings from a multicenter prospective observational study. BMC Infect Dis 2014; 14:725.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/14\" class=\"nounderline abstract_t\">Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/15\" class=\"nounderline abstract_t\">Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/16\" class=\"nounderline abstract_t\">Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/17\" class=\"nounderline abstract_t\">Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/18\" class=\"nounderline abstract_t\">Abele-Horn M, Kopp A, Sternberg U, et al. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients. Infection 1996; 24:426.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/19\" class=\"nounderline abstract_t\">Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/20\" class=\"nounderline abstract_t\">Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/21\" class=\"nounderline abstract_t\">Presterl E, Graninger W. Efficacy and safety of fluconazole in the treatment of systemic fungal infections in pediatric patients. Multicentre Study Group. Eur J Clin Microbiol Infect Dis 1994; 13:347.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/22\" class=\"nounderline abstract_t\">Schwarze R, Penk A, Pittrow L. Treatment of candidal infections with fluconazole in neonates and infants. Eur J Med Res 2000; 5:203.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/23\" class=\"nounderline abstract_t\">Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/24\" class=\"nounderline abstract_t\">Thompson GR 3rd, Wiederhold NP, Vallor AC, et al. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 2008; 52:3783.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/25\" class=\"nounderline abstract_t\">Costa-de-Oliveira S, Marcos Miranda I, Silva RM, et al. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy. Antimicrob Agents Chemother 2011; 55:1312.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/26\" class=\"nounderline abstract_t\">Pfeiffer CD, Garcia-Effron G, Zaas AK, et al. Breakthrough invasive candidiasis in patients on micafungin. J Clin Microbiol 2010; 48:2373.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/27\" class=\"nounderline abstract_t\">Zaoutis TE, Prasad PA, Localio AR, et al. Risk factors and predictors for candidemia in pediatric intensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51:e38.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/28\" class=\"nounderline abstract_t\">Zaoutis TE, Greves HM, Lautenbach E, et al. Risk factors for disseminated candidiasis in children with candidemia. Pediatr Infect Dis J 2004; 23:635.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/29\" class=\"nounderline abstract_t\">Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/30\" class=\"nounderline abstract_t\">Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Clin Infect Dis 1995; 21:994.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/31\" class=\"nounderline abstract_t\">Asmundsd&oacute;ttir LR, Erlendsd&oacute;ttir H, Gottfredsson M. Improving survival of patients with candidaemia: analysis of prognostic factors from a long-term, nationwide study in Iceland. Scand J Infect Dis 2005; 37:111.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/32\" class=\"nounderline abstract_t\">Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995; 20:571.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/33\" class=\"nounderline abstract_t\">Fisher BT, Vendetti N, Bryan M, et al. Central Venous Catheter Retention and Mortality in Children With Candidemia: A Retrospective Cohort Analysis. J Pediatric Infect Dis Soc 2016; 5:403.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/34\" class=\"nounderline abstract_t\">Buckler BS, Sams RN, Goei VL, et al. Treatment of central venous catheter fungal infection using liposomal amphotericin-B lock therapy. Pediatr Infect Dis J 2008; 27:762.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/35\" class=\"nounderline abstract_t\">Castagnola E, Marazzi MG, Tacchella A, Giacchino R. Broviac catheter-related candidemia. Pediatr Infect Dis J 2005; 24:747.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/36\" class=\"nounderline abstract_t\">Viale P, Petrosillo N, Signorini L, et al. Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections? Clin Infect Dis 2001; 33:1947.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/37\" class=\"nounderline abstract_t\">Johnson DC, Johnson FL, Goldman S. Preliminary results treating persistent central venous catheter infections with the antibiotic lock technique in pediatric patients. Pediatr Infect Dis J 1994; 13:930.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/38\" class=\"nounderline abstract_t\">McGhee W, Michaels MG, Martin JM, et al. Antifungal Lock Therapy with Liposomal Amphotericin B: A Prospective Trial. J Pediatric Infect Dis Soc 2016; 5:80.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/39\" class=\"nounderline abstract_t\">Pieroni KP, Nespor C, Poole RL, et al. Echinocandin and ethanol lock therapy treatment of fungal catheter infections. Pediatr Infect Dis J 2013; 32:289.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/40\" class=\"nounderline abstract_t\">Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/41\" class=\"nounderline abstract_t\">Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis 2012; 54:1110.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/42\" class=\"nounderline abstract_t\">Clancy CJ, Nguyen MH. The end of an era in defining the optimal treatment of invasive candidiasis. Clin Infect Dis 2012; 54:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/43\" class=\"nounderline abstract_t\">Dutta A, Zaoutis TE, Palazzi DL. An update on the epidemiology of candidemia in children. Curr Fungal Infect Rep 2012; 6:296.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/44\" class=\"nounderline abstract_t\">Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36:2967.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/45\" class=\"nounderline abstract_t\">Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37:634.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/46\" class=\"nounderline abstract_t\">Cortegiani A, Russotto V, Maggiore A, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. Cochrane Database Syst Rev 2016; :CD004920.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/47\" class=\"nounderline abstract_t\">Blyth CC, Hale K, Palasanthiran P, et al. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev 2010; :CD006343.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/48\" class=\"nounderline abstract_t\">Prasad PA, Coffin SE, Leckerman KH, et al. Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 2008; 27:1083.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/49\" class=\"nounderline abstract_t\">Palazzi DL, Arrieta A, Castagnola E, et al. Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study. Pediatr Infect Dis J 2014; 33:1294.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/50\" class=\"nounderline abstract_t\">Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 2009; 4:1832.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/51\" class=\"nounderline abstract_t\">Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997; 41:1944.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/52\" class=\"nounderline abstract_t\">Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/53\" class=\"nounderline abstract_t\">Lee JW, Seibel NL, Amantea M, et al. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J Pediatr 1992; 120:987.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/54\" class=\"nounderline abstract_t\">Seay RE, Larson TA, Toscano JP, et al. Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases. Pharmacotherapy 1995; 15:52.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/55\" class=\"nounderline abstract_t\">Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/56\" class=\"nounderline abstract_t\">Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53:935.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/57\" class=\"nounderline abstract_t\">Br&uuml;ggemann RJ, van der Linden JW, Verweij PE, et al. Impact of therapeutic drug monitoring of voriconazole in a pediatric population. Pediatr Infect Dis J 2011; 30:533.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/58\" class=\"nounderline abstract_t\">Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/59\" class=\"nounderline abstract_t\">Smith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50:1570.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/60\" class=\"nounderline abstract_t\">Neely M, Rushing T, Kovacs A, et al. Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 2010; 50:27.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/61\" class=\"nounderline abstract_t\">Doby EH, Benjamin DK Jr, Blaschke AJ, et al. Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J 2012; 31:632.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/62\" class=\"nounderline abstract_t\">Pieper S, Kolve H, Gumbinger HG, et al. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother 2012; 67:2717.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/63\" class=\"nounderline abstract_t\">Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/64\" class=\"nounderline abstract_t\">Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/65\" class=\"nounderline abstract_t\">Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/66\" class=\"nounderline abstract_t\">Zaoutis T, Lehrnbecher T, Groll AH, et al. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 2009; 28:1132.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/67\" class=\"nounderline abstract_t\">Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005; 18:484.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/68\" class=\"nounderline abstract_t\">Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/69\" class=\"nounderline abstract_t\">Fisher BT, Zaoutis T. Caspofungin for the treatment of pediatric fungal infections. Pediatr Infect Dis J 2008; 27:1099.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/70\" class=\"nounderline abstract_t\">Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123:877.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/71\" class=\"nounderline abstract_t\">Maertens JA, Madero L, Reilly AF, et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29:415.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/72\" class=\"nounderline abstract_t\">Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J 2011; 30:e97.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/73\" class=\"nounderline abstract_t\">Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J 2014; 33:e291.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/74\" class=\"nounderline abstract_t\">Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/75\" class=\"nounderline abstract_t\">Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/76\" class=\"nounderline abstract_t\">Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/77\" class=\"nounderline abstract_t\">Cohen-Wolkowiez M, Moran C, Benjamin DK Jr, Smith PB. Pediatric antifungal agents. Curr Opin Infect Dis 2009; 22:553.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/78\" class=\"nounderline abstract_t\">Undre NA, Stevenson P, Freire A, Arrieta A. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia. Pediatr Infect Dis J 2012; 31:630.</a></li><li><a href=\"https://www.uptodate.com/contents/candidemia-and-invasive-candidiasis-in-children-management/abstract/79\" class=\"nounderline abstract_t\">Benjamin DK Jr, Deville JG, Azie N, et al. Safety and pharmacokinetic profiles of repeated-dose micafungin in children and adolescents treated for invasive candidiasis. Pediatr Infect Dis J 2013; 32:e419.</a></li><li class=\"breakAll\">Mycamine (micafungin sodium) injection. US Food &amp; Drug Administration (FDA) approved product information. Revised June, 2013. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on June 10, 2014).</li></ol></div><div id=\"topicVersionRevision\">Topic 6014 Version 20.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H275376660\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H3500291199\" id=\"outline-link-H3500291199\">HIGH SUSPICION FOR INVASIVE CANDIDIASIS</a></li><li><a href=\"#H2519417445\" id=\"outline-link-H2519417445\">DOCUMENTED INVASIVE CANDIDIASIS</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Choice of antifungal therapy</a><ul><li><a href=\"#H2519344657\" id=\"outline-link-H2519344657\">- Pending speciation and susceptibility testing</a></li><li><a href=\"#H275376940\" id=\"outline-link-H275376940\">- Targeted therapy</a></li></ul></li><li><a href=\"#H237362476\" id=\"outline-link-H237362476\">Monitoring response</a><ul><li><a href=\"#H2508085457\" id=\"outline-link-H2508085457\">- Persistent candidemia</a></li></ul></li><li><a href=\"#H1550496714\" id=\"outline-link-H1550496714\">Duration of antifungal therapy</a><ul><li><a href=\"#H2235653712\" id=\"outline-link-H2235653712\">- Suggested duration</a></li><li><a href=\"#H1715923409\" id=\"outline-link-H1715923409\">- Switching to oral therapy</a></li></ul></li><li><a href=\"#H2934778652\" id=\"outline-link-H2934778652\">Source control</a><ul><li><a href=\"#H3634349987\" id=\"outline-link-H3634349987\">- Central venous catheter</a></li><li><a href=\"#H3275888630\" id=\"outline-link-H3275888630\">- Other foci of infection</a></li></ul></li><li><a href=\"#H1984269720\" id=\"outline-link-H1984269720\">Outcome</a></li></ul></li><li><a href=\"#H1402641259\" id=\"outline-link-H1402641259\">EMPIRIC ANTIFUNGAL THERAPY FOR AT-RISK PATIENTS</a><ul><li><a href=\"#H2317282572\" id=\"outline-link-H2317282572\">Nonneutropenic patients</a></li><li><a href=\"#H1829865803\" id=\"outline-link-H1829865803\">Neutropenic patients</a></li></ul></li><li><a href=\"#H327877656\" id=\"outline-link-H327877656\">ANTIFUNGAL AGENTS</a><ul><li><a href=\"#H2040771150\" id=\"outline-link-H2040771150\">Amphotericin B deoxycholate</a></li><li><a href=\"#H2445034808\" id=\"outline-link-H2445034808\">Lipid amphotericin B</a></li><li><a href=\"#H1313370116\" id=\"outline-link-H1313370116\">Azole antifungal agents</a></li><li><a href=\"#H2984100972\" id=\"outline-link-H2984100972\">Echinocandins</a></li></ul></li><li><a href=\"#H4053869140\" id=\"outline-link-H4053869140\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H275376660\" id=\"outline-link-H275376660\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H1726014949\" id=\"outline-link-H1726014949\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/6014|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58685\" class=\"graphic graphic_picture\">- Candida endophthalmitis</a></li><li><a href=\"image.htm?imageKey=ID/73318\" class=\"graphic graphic_picture\">- Vitritis in endophthalmitis</a></li><li><a href=\"image.htm?imageKey=ID/55977\" class=\"graphic graphic_picture\">- Disseminated candidiasis skin</a></li><li><a href=\"image.htm?imageKey=ID/75717\" class=\"graphic graphic_picture\">- Disseminated candidiasis nodule</a></li></ul></li><li><div id=\"PEDS/6014|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/109381\" class=\"graphic graphic_table\">- Rx invasive candidiasis in children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=amphotericin-b-nephrotoxicity\" class=\"medical medical_review\">Amphotericin B nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=candida-infections-in-children\" class=\"medical medical_review\">Candida infections in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=candidemia-and-invasive-candidiasis-in-children-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Candidemia and invasive candidiasis in children: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candida-infection-in-neonates\" class=\"medical medical_review\">Clinical manifestations and diagnosis of Candida infection in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-pathogenesis-of-candidemia-in-adults\" class=\"medical medical_review\">Epidemiology and pathogenesis of candidemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-and-risk-factors-for-candida-infection-in-neonates\" class=\"medical medical_review\">Epidemiology and risk factors for Candida infection in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-and-management-of-fever-in-children-with-non-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">Evaluation and management of fever in children with non-chemotherapy-induced neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fever-in-children-with-chemotherapy-induced-neutropenia\" class=\"medical medical_review\">Fever in children with chemotherapy-induced neutropenia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infective-endocarditis-in-children\" class=\"medical medical_review\">Infective endocarditis in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">Pharmacology of amphotericin B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-candidiasis\" class=\"medical medical_society_guidelines\">Society guideline links: Candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candida-infection-in-neonates\" class=\"medical medical_review\">Treatment of Candida infection in neonates</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-candidemia-and-invasive-candidiasis-in-adults\" class=\"medical medical_review\">Treatment of candidemia and invasive candidiasis in adults</a></li></ul></div></div>","javascript":null}